{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-24-000058","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.255116+00:00","generated_at":"2026-06-01T09:11:55.422876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medtronic reports Q4 FY24 revenue $8.59B, organic growth 5.4%; FY25 EPS guidance $5.40-$5.50","bullets":["Q4 GAAP diluted EPS $0.49, non-GAAP $1.46; FY24 GAAP diluted EPS $2.76, non-GAAP $5.20.","FY24 revenue $32.4B (+3.6% reported, +5.2% organic); Q4 revenue $8.59B (+0.5% reported, +5.4% organic).","FY25 guidance: organic revenue growth 4%-5%; non-GAAP EPS $5.40-$5.50 (4-6% growth).","Dividend increased to $0.70 quarterly ($2.80 annual), 47th consecutive year of dividend increase.","Broad-based organic growth: Neuroscience +6.5%, Cardiovascular +4.0%, Medical Surgical +4.5%, Diabetes +11.1% in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-24-000058","json":"https://secwatch.observer/filing/0001613103-24-000058.json","markdown":"https://secwatch.observer/filing/0001613103-24-000058.md","text":"https://secwatch.observer/filing/0001613103-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000058/0001613103-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000058/mdt-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:11:55.422876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}